Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin

Deborah E. Briggs, Caroline M. Lee, Katharyn Spiegel, Jacqueline A. French

Research output: Contribution to journalArticle

Abstract

Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.

Original languageEnglish (US)
Pages (from-to)88-94
Number of pages7
JournalEpilepsy Research
Volume82
Issue number1
DOIs
StatePublished - Nov 2008

Fingerprint

Seizures
Placebos
Pregabalin
Therapeutics
Maximum Tolerated Dose
Partial Epilepsy
Anticonvulsants
Epilepsy
Outcome Assessment (Health Care)

Keywords

  • Placebo-controlled study
  • Pregabalin
  • Refractory partial epilepsy
  • Secondarily generalized tonic-clonic
  • Seizure reduction

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. / Briggs, Deborah E.; Lee, Caroline M.; Spiegel, Katharyn; French, Jacqueline A.

In: Epilepsy Research, Vol. 82, No. 1, 11.2008, p. 88-94.

Research output: Contribution to journalArticle

Briggs, Deborah E. ; Lee, Caroline M. ; Spiegel, Katharyn ; French, Jacqueline A. / Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. In: Epilepsy Research. 2008 ; Vol. 82, No. 1. pp. 88-94.
@article{b3b64876d8a54b6eaff40d273dc91a0e,
title = "Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin",
abstract = "Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.",
keywords = "Placebo-controlled study, Pregabalin, Refractory partial epilepsy, Secondarily generalized tonic-clonic, Seizure reduction",
author = "Briggs, {Deborah E.} and Lee, {Caroline M.} and Katharyn Spiegel and French, {Jacqueline A.}",
year = "2008",
month = "11",
doi = "10.1016/j.eplepsyres.2008.07.004",
language = "English (US)",
volume = "82",
pages = "88--94",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin

AU - Briggs, Deborah E.

AU - Lee, Caroline M.

AU - Spiegel, Katharyn

AU - French, Jacqueline A.

PY - 2008/11

Y1 - 2008/11

N2 - Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.

AB - Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.

KW - Placebo-controlled study

KW - Pregabalin

KW - Refractory partial epilepsy

KW - Secondarily generalized tonic-clonic

KW - Seizure reduction

UR - http://www.scopus.com/inward/record.url?scp=55649083718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649083718&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2008.07.004

DO - 10.1016/j.eplepsyres.2008.07.004

M3 - Article

VL - 82

SP - 88

EP - 94

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -